반응식
[F:1][C:2]1[CH:7]=[CH:6][C:5]([C:8]2([OH:19])[CH2:11][N:10]([C:12](OC(C)(C)C)=O)[CH2:9]2)=[CH:4][CH:3]=1.ClC1[N:30]=[CH:29][C:28]([Cl:31])=[CH:27][C:22]=1[C:23]([O:25][CH3:26])=[O:24]>>[Cl:31][C:28]1[CH:29]=[N:30][C:12]([N:10]2[CH2:9][C:8]([C:5]3[CH:4]=[CH:3][C:2]([F:1])=[CH:7][CH:6]=3)([OH:19])[CH2:11]2)=[C:22]([CH:27]=1)[C:23]([O:25][CH3:26])=[O:24]참가 물질
3
실험 절차
The title compound (D81) (0021/074/1) (75.9 mg) was prepared according to the experimental procedure described in Description 80 starting from tert-butyl 3-(4-fluorophenyl)-3-hydroxyazetidine-1-carboxylate (D29) (100 mg, 0.374 mmol) and methyl 2,5-dichloronicotinate (77.32 mg, 0.374 mmol).
출처 및 근거
- ORD 기록
- ord-d3bb85cc8ad3477ba58a356b34090d63
- 출처 데이터셋
- uspto-grants-2014_09
- 특허 번호
- US08828987B2
연결된 노트
불러오는 중…